2021
Neurological manifestations as the predictors of severity and mortality in hospitalized individuals with COVID-19: a multicenter prospective clinical study
Amanat M, Rezaei N, Roozbeh M, Shojaei M, Tafakhori A, Zoghi A, Darazam IA, Salehi M, Karimialavijeh E, Lima BS, Garakani A, Vaccaro A, Ramezani M. Neurological manifestations as the predictors of severity and mortality in hospitalized individuals with COVID-19: a multicenter prospective clinical study. BMC Neurology 2021, 21: 116. PMID: 33726699, PMCID: PMC7960879, DOI: 10.1186/s12883-021-02152-5.Peer-Reviewed Original ResearchConceptsShortness of breathPredictors of severityTaste dysfunctionNeurological manifestationsNeurological symptomsSevere casesCOVID-19Multicenter prospective clinical studyMulti-center prospective studyHyposmia/anosmiaGuillain-Barré syndromeWeeks of dischargeProspective clinical studyCommon neurological symptomsTime of admissionNon-neurological manifestationsCoronavirus disease 2019COVID-19 diseaseCerebrovascular eventsChest tightnessStatus epilepticusEligible casesNeurological findingsProspective studyMild headache
2020
The effects of augmenting clozapine with oxytocin in schizophrenia: An initial case series.
Marotta RF, Buono FD, Garakani A, Collins E, Cerrito B, David Rowe DR. The effects of augmenting clozapine with oxytocin in schizophrenia: An initial case series. Annals Of Clinical Psychiatry 2020, 32: 90-96. PMID: 32343282.Peer-Reviewed Case Reports and Technical NotesConceptsTreatment-resistant schizophreniaNegative symptomsAtypical antipsychoticsRetrospective chart reviewInitial case seriesAugmentation of clozapineChronic psychotic illnessNegative Syndrome ScaleYoung adult inpatientsSymptoms of schizophreniaParent/guardian reportsChart reviewCase seriesAdult inpatientsProspective studyAntipsychotic medicationClinical reviewTherapeutic responsePsychotic illnessTreatment approachesSyndrome ScalePositive symptomsTreating psychiatristSymptomsSustained treatment